Fingolimod (Gilenya), the first FDA-approved oral disease-modifying drug for the treatment of MS, reduces serum levels of HMGB1 in patients which may be a suggested marker for clinical relapse (78). The gene discussed is HMGB1; the disease is myeloid sarcoma.